EGFR and neoplasm: T790M mutation status at first progression was evaluated in 68 patients treated with first generation EGFR-TKIs in both groups using tumor tissue samples or peripheral blood cell-free tumor DNA, forty-four (64.7%) patients were finally confirmed to have a T790M mutation at their first progression.